Company intelligence / Profile preview
Aldagen
Durham, North Carolina, United Statesbiospace.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Phase 2
01
Overview
Aldagen developed technology for selecting stem cells with higher potency from adult sources using aldehyde dehydrogenase (ALDH). Their most advanced program, ALD-101, was a purified cord blood stem cell product for treating inherited metabolic diseases in pediatric patients that reached Phase III trials. They also developed ALD-201, which used patients' own bone marrow-derived stem cells for treating chronic heart failure, which completed Phase I trials.
- Therapeutic areas
- CardiovascularMetabolic DisordersHematologyOncologyNeurology
- Modalities
- Regenerative cell therapiesStem cell therapies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Aldagen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aldagen.